Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Immuron (IMRN) Gross Margin (2016 - 2024)

Immuron's quarterly Gross Margin came in at 66.52% in Q4 2024, down 57.0% year-on-year from 154.7% in Q1 2024, and down 0.85% quarter-over-quarter from 67.09% in Q4 2023.

Immuron has reported Gross Margin for 9 years, with the latest figure at 66.52% in Q4 2024.

  • For the quarter ending Q4 2024, Gross Margin fell 57.0% year-over-year to 66.52%; the trailing twelve-month figure through Dec 2024 stood at 66.52% (up 6640.0% YoY), and the FY2025 full-year result was 65.39%, down 267.0% from the prior year.
  • Gross Margin for Q4 2024 stood at 66.52%, down from 67.09% in the prior quarter.
  • The five-year high for Gross Margin was 82.75% in Q2 2023, with the low at 0.0% in Q4 2021.
  • Average Gross Margin over 5 years is 54.7%, with a median of 66.8% recorded in 2023.
  • Year-over-year, Gross Margin slumped 3853 bps in 2021 and surged 7332 bps in 2022.
  • Tracing IMRN's Gross Margin over 5 years: stood at 38.53% in 2020, then plunged by 100 bps to 0.0% in 2021, then soared by 104824652 bps to 73.32% in 2022, then dropped by 8 bps to 67.09% in 2023, then retreated by 1 bps to 66.52% in 2024.
  • The last three Gross Margin figures came in at 66.52% (Q4 2024), 67.09% (Q4 2023), and 82.75% (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 86.85%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 82.22%
10 Immuron 1.27 Bn 1.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 66.52%
Dec 31, 2023 67.09%
Jun 30, 2023 82.75%
Dec 31, 2022 73.32%
Dec 31, 2021 0.00%
Dec 31, 2020 38.53%
Dec 31, 2019 72.04%
Dec 31, 2018 76.34%
Dec 31, 2017 78.75%
Dec 31, 2016 68.23%
Jun 30, 2016 73.91%